Bioventus Inc. Secures FDA 510(k) Clearance for TalisMann™ and StimTrial™ Peripheral Nerve Stimulation Products

Reuters

07-31

<a href="https://laohu8.com/S/BVS">Bioventus Inc.</a> Secures FDA 510(k) Clearance for TalisMann™ and StimTrial™ Peripheral Nerve Stimulation Products

Bioventus Inc., a leader in active healing innovations, announced a major achievement on July 30, 2025, with the U.S. Food and Drug Administration (FDA) granting 510(k) clearances for its two next-generation Peripheral Nerve Stimulation $(PNS.UK)$ products, TalisMann™ and StimTrial™. These approvals mark a significant milestone for Bioventus, expanding its innovative PNS solutions aimed at chronic pain management. The company plans a limited commercial release in selected U.S. markets during the third quarter, with a broader rollout anticipated in early 2026. This development reinforces Bioventus' commitment to delivering non-opioid, minimally invasive therapies, presenting a substantial growth opportunity in a PNS market projected to exceed $500 million by 2029.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioventus Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001665988-25-000013), on July 31, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2555838524"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2555838524\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2555838524?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-31 20:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2555838524","market":"nz","top_or_hot":-1,"title":"Bioventus Inc. Secures FDA 510(k) Clearance for TalisMann™ and StimTrial™ Peripheral Nerve Stimulation Products","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/BVS\">Bioventus Inc.</a> Secures FDA 510(k) Clearance for TalisMann™ and StimTrial™ Peripheral Nerve Stimulation Products\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Bioventus Inc., a leader in active healing innovations, announced a major achievement on July 30, 2025, with the U.S. Food and Drug Administration (FDA) granting 510(k) clearances for its two next-generation Peripheral Nerve Stimulation <a href=\"https://laohu8.com/S/PNS.UK\">$(PNS.UK)$</a> products, TalisMann™ and StimTrial™. These approvals mark a significant milestone for Bioventus, expanding its innovative PNS solutions aimed at chronic pain management. The company plans a limited commercial release in selected U.S. markets during the third quarter, with a broader rollout anticipated in early 2026. This development reinforces Bioventus' commitment to delivering non-opioid, minimally invasive therapies, presenting a substantial growth opportunity in a PNS market projected to exceed $500 million by 2029.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioventus Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001665988-25-000013), on July 31, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bioventus Inc. Secures FDA 510(k) Clearance for TalisMann™ and StimTrial™ Peripheral Nerve Stimulation Products</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioventus Inc. Secures FDA 510(k) Clearance for TalisMann™ and StimTrial™ Peripheral Nerve Stimulation Products\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-07-31 20:13</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/BVS\">Bioventus Inc.</a> Secures FDA 510(k) Clearance for TalisMann™ and StimTrial™ Peripheral Nerve Stimulation Products\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Bioventus Inc., a leader in active healing innovations, announced a major achievement on July 30, 2025, with the U.S. Food and Drug Administration (FDA) granting 510(k) clearances for its two next-generation Peripheral Nerve Stimulation <a href=\"https://laohu8.com/S/PNS.UK\">$(PNS.UK)$</a> products, TalisMann™ and StimTrial™. These approvals mark a significant milestone for Bioventus, expanding its innovative PNS solutions aimed at chronic pain management. The company plans a limited commercial release in selected U.S. markets during the third quarter, with a broader rollout anticipated in early 2026. This development reinforces Bioventus' commitment to delivering non-opioid, minimally invasive therapies, presenting a substantial growth opportunity in a PNS market projected to exceed $500 million by 2029.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioventus Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001665988-25-000013), on July 31, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BVS","symbol_name":"Bioventus Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250731:nNDL1B0m1N:1","article_id":"2555838524","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2555838524","pubTimestamp":1753964000,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Bioventus Inc., a leader in active healing innovations, announced a major achievement on July 30, 2025, with the U.S. Food and Drug Administration  granting 510 clearances for its two next-generation Peripheral Nerve Stimulation  products, TalisMann and StimTrial. These approvals mark a significant milestone for Bioventus, expanding its innovative PNS solutions aimed at chronic pain management. The company plans a limited commercial release in selected U.S. markets during the third quarter, with a broader rollout anticipated in early 2026. This development reinforces Bioventus' commitment to delivering non-opioid, minimally invasive therapies, presenting a substantial growth opportunity in a PNS market projected to exceed $500 million by 2029.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BVS":"Bioventus Inc.","BK4198":"医疗保健用品"},"translate_title":"Bioventus Inc.获得Talismann FDA 510(k)许可™和刺激试验™周围神经刺激产品","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BVS":0.9},"content_text":"Bioventus Inc. Secures FDA 510(k) Clearance for TalisMann™ and StimTrial™ Peripheral Nerve Stimulation Products\n    \n\n        Bioventus Inc., a leader in active healing innovations, announced a major achievement on July 30, 2025, with the U.S. Food and Drug Administration (FDA) granting 510(k) clearances for its two next-generation Peripheral Nerve Stimulation $(PNS.UK)$ products, TalisMann™ and StimTrial™. These approvals mark a significant milestone for Bioventus, expanding its innovative PNS solutions aimed at chronic pain management. The company plans a limited commercial release in selected U.S. markets during the third quarter, with a broader rollout anticipated in early 2026. This development reinforces Bioventus' commitment to delivering non-opioid, minimally invasive therapies, presenting a substantial growth opportunity in a PNS market projected to exceed $500 million by 2029.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioventus Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001665988-25-000013), on July 31, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}